• Je něco špatně v tomto záznamu ?

Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency

V. Valayannopoulos, V. Malinova, T. Honzík, M. Balwani, C. Breen, PB. Deegan, GM. Enns, SA. Jones, JP. Kane, EO. Stock, R. Tripuraneni, S. Eckert, E. Schneider, G. Hamilton, MS. Middleton, C. Sirlin, B. Kessler, C. Bourdon, SA. Boyadjiev, R....

. 2014 ; 61 (5) : 1135-42.

Jazyk angličtina Země Nizozemsko

Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15023282

BACKGROUND & AIMS: Lysosomal acid lipase deficiency is an autosomal recessive enzyme deficiency resulting in lysosomal accumulation of cholesteryl esters and triglycerides. LAL-CL04, an ongoing extension study, investigates the long-term effects of sebelipase alfa, a recombinant human lysosomal acid lipase. METHODS: Sebelipase alfa (1mg/kg or 3mg/kg) was infused every-other-week to eligible subjects. Safety and tolerability assessments, including liver function, lipid profiles and liver volume assessment, were carried out at regular intervals. RESULTS: 216 infusions were administered to eight adult subjects through week 52 during LAL-CL04. At week 52, mean alanine aminotransferase and aspartate aminotransferase levels were normal with mean change from baseline of -58% and -40%. Mean changes for low-density lipoprotein, total cholesterol, triglyceride and high-density lipoprotein were -60%, -39%, -36%, and +29%, respectively. Mean liver volume by magnetic resonance imaging and hepatic proton density fat fraction decreased (12% and 55%, respectively). Adverse events were mainly mild and unrelated to sebelipase alfa. Infusion-related reactions were uncommon: three events of moderate severity were reported in two subjects; one patient's event was suggestive of a hypersensitivity-like reaction, but additional testing did not confirm this, and the subject has successfully re-started sebelipase alfa. Of samples tested to date, no anti-drug antibodies have been detected. CONCLUSIONS: Long-term dosing with sebelipase alfa in lysosomal acid lipase-deficient patients is well tolerated and produces sustained reductions in transaminases, improvements in serum lipid profile and reduction in the hepatic fat fraction. A randomized, placebo-controlled phase 3 trial in children and adults is underway (ARISE: NCT01757184).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15023282
003      
CZ-PrNML
005      
20150729113025.0
007      
ta
008      
150709s2014 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jhep.2014.06.022 $2 doi
035    __
$a (PubMed)24993530
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Valayannopoulos, Vassili $u Ref Centre IEM, Necker-Enf Malades Hosp, IMAGINE Institute and Paris Descartes University, Paris, France.
245    10
$a Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency / $c V. Valayannopoulos, V. Malinova, T. Honzík, M. Balwani, C. Breen, PB. Deegan, GM. Enns, SA. Jones, JP. Kane, EO. Stock, R. Tripuraneni, S. Eckert, E. Schneider, G. Hamilton, MS. Middleton, C. Sirlin, B. Kessler, C. Bourdon, SA. Boyadjiev, R. Sharma, C. Twelves, CB. Whitley, AG. Quinn,
520    9_
$a BACKGROUND & AIMS: Lysosomal acid lipase deficiency is an autosomal recessive enzyme deficiency resulting in lysosomal accumulation of cholesteryl esters and triglycerides. LAL-CL04, an ongoing extension study, investigates the long-term effects of sebelipase alfa, a recombinant human lysosomal acid lipase. METHODS: Sebelipase alfa (1mg/kg or 3mg/kg) was infused every-other-week to eligible subjects. Safety and tolerability assessments, including liver function, lipid profiles and liver volume assessment, were carried out at regular intervals. RESULTS: 216 infusions were administered to eight adult subjects through week 52 during LAL-CL04. At week 52, mean alanine aminotransferase and aspartate aminotransferase levels were normal with mean change from baseline of -58% and -40%. Mean changes for low-density lipoprotein, total cholesterol, triglyceride and high-density lipoprotein were -60%, -39%, -36%, and +29%, respectively. Mean liver volume by magnetic resonance imaging and hepatic proton density fat fraction decreased (12% and 55%, respectively). Adverse events were mainly mild and unrelated to sebelipase alfa. Infusion-related reactions were uncommon: three events of moderate severity were reported in two subjects; one patient's event was suggestive of a hypersensitivity-like reaction, but additional testing did not confirm this, and the subject has successfully re-started sebelipase alfa. Of samples tested to date, no anti-drug antibodies have been detected. CONCLUSIONS: Long-term dosing with sebelipase alfa in lysosomal acid lipase-deficient patients is well tolerated and produces sustained reductions in transaminases, improvements in serum lipid profile and reduction in the hepatic fat fraction. A randomized, placebo-controlled phase 3 trial in children and adults is underway (ARISE: NCT01757184).
650    _2
$a dospělí $7 D000328
650    _2
$a alanintransaminasa $x krev $7 D000410
650    _2
$a aspartátaminotransferasy $x krev $7 D001219
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lipidy $x krev $7 D008055
650    _2
$a játra $x patologie $7 D008099
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a rekombinantní proteiny $x aplikace a dávkování $x škodlivé účinky $7 D011994
650    _2
$a sterolesterasa $x aplikace a dávkování $x škodlivé účinky $x nedostatek $7 D002787
650    _2
$a Wolmanova nemoc $x krev $x farmakoterapie $x patologie $7 D015223
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Malinova, Vera $u Department of Pediatrics, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Honzík, Tomas $u Department of Pediatrics, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Balwani, Manisha $u Department of Genetics and Genomic Sciences, The Mount Sinai School of Medicine, New York, NY, United States.
700    1_
$a Breen, Catherine $u Manchester Centre for Genomic Medicine, St. Mary's Hospital, Manchester, UK.
700    1_
$a Deegan, Patrick B $u Department of Medicine, Addenbrooke's Hospital, Cambridge, UK.
700    1_
$a Enns, Gregory M $u Department of Pediatrics, Lucile Packard Children's Hospital, Stanford University, Stanford, CA, United States.
700    1_
$a Jones, Simon A $u Manchester Centre for Genomic Medicine, St. Mary's Hospital, Manchester, UK.
700    1_
$a Kane, John P $u Divisions of Endocrinology & Metabolism, University of California, San Francisco, CA, United States.
700    1_
$a Stock, Eveline O $u Divisions of Cardiology, University of California, San Francisco, CA, United States.
700    1_
$a Tripuraneni, Radhika $u Synageva BioPharma Corp., Lexington, MA, United States.
700    1_
$a Eckert, Stephen $u Synageva BioPharma Corp., Lexington, MA, United States.
700    1_
$a Schneider, Eugene $u Synageva BioPharma Corp., Lexington, MA, United States.
700    1_
$a Hamilton, Gavin $u University of California, San Diego, CA, United States.
700    1_
$a Middleton, Michael S $u University of California, San Diego, CA, United States.
700    1_
$a Sirlin, Claude $u University of California, San Diego, CA, United States.
700    1_
$a Kessler, Bruce $u Eureka Internal Medicine, Eureka, CA, United States.
700    1_
$a Bourdon, Christopher $u Health Sciences North, Sudbury, Ontario, Canada.
700    1_
$a Boyadjiev, Simeon A $u University of California, Davis Medical Center, Department of Pediatrics, Section of Genetics, Davis, CA, United States.
700    1_
$a Sharma, Reena $u Salford Royal NHS Foundation Trust, Salford, UK.
700    1_
$a Twelves, Chris $u Leeds Institute of Cancer and Pathology, Leeds, UK.
700    1_
$a Whitley, Chester B $u University of Minnesota, Minneapolis, MN, United States.
700    1_
$a Quinn, Anthony G $u Synageva BioPharma Corp., Lexington, MA, United States. Electronic address: Anthony.Quinn@synageva.com.
773    0_
$w MED00010017 $t Journal of hepatology $x 1600-0641 $g Roč. 61, č. 5 (2014), s. 1135-42
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24993530 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20150729113111 $b ABA008
999    __
$a ok $b bmc $g 1083620 $s 906275
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 61 $c 5 $d 1135-42 $i 1600-0641 $m Journal of hepatology $n J Hepatol $x MED00010017
LZP    __
$a Pubmed-20150709

Najít záznam

Citační ukazatele

Možnosti archivace